NCT06869018View on ClinicalTrials.gov

A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
HealthyType 2 Diabetes Mellitus (T2D)
Interventions
DRUG

LY3549492

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (4)

812-0025

RECRUITING

Hakata Clinic, Fukuoka

192-0071

RECRUITING

P-One Clinic, Hachiōji

532-0003

RECRUITING

Medical Corporation Heishinkai OPHAC Hospital, Osaka

160-0004

RECRUITING

Clinical Research Hospital Tokyo, Shinjuku-ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY